CA3086535A1 - Crystalline forms of nicotinamide riboside chloride - Google Patents

Crystalline forms of nicotinamide riboside chloride Download PDF

Info

Publication number
CA3086535A1
CA3086535A1 CA3086535A CA3086535A CA3086535A1 CA 3086535 A1 CA3086535 A1 CA 3086535A1 CA 3086535 A CA3086535 A CA 3086535A CA 3086535 A CA3086535 A CA 3086535A CA 3086535 A1 CA3086535 A1 CA 3086535A1
Authority
CA
Canada
Prior art keywords
crystalline form
subject
administering
solution
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3086535A
Other languages
English (en)
French (fr)
Inventor
Eric MARCOTULLI
Dan ALMINANA
Ryan DELLINGER
Mark Morris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elysium Health Inc
Original Assignee
Elysium Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elysium Health Inc filed Critical Elysium Health Inc
Publication of CA3086535A1 publication Critical patent/CA3086535A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA3086535A 2017-12-22 2018-12-20 Crystalline forms of nicotinamide riboside chloride Pending CA3086535A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762609512P 2017-12-22 2017-12-22
US62/609,512 2017-12-22
PCT/US2018/066769 WO2019126482A1 (en) 2017-12-22 2018-12-20 Crystalline forms of nicotinamide riboside chloride

Publications (1)

Publication Number Publication Date
CA3086535A1 true CA3086535A1 (en) 2019-06-27

Family

ID=66993830

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3086535A Pending CA3086535A1 (en) 2017-12-22 2018-12-20 Crystalline forms of nicotinamide riboside chloride

Country Status (6)

Country Link
US (2) US11414407B2 (cg-RX-API-DMAC7.html)
EP (1) EP3727400A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021506898A (cg-RX-API-DMAC7.html)
CN (1) CN112020363A (cg-RX-API-DMAC7.html)
CA (1) CA3086535A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019126482A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11129843B2 (en) 2017-04-24 2021-09-28 Elysium Health, Inc. Treating and preventing kidney damage
EP3727400A4 (en) 2017-12-22 2021-10-20 Elysium Health, Inc. CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE
JP7675061B2 (ja) 2019-07-19 2025-05-12 バイオシント アクチェンゲゼルシャフト ニコチンアミドリボフラノシド塩の製造方法、ニコチンアミドリボフラノシド塩自体、およびその使用
CN111454311B (zh) 2020-04-03 2021-10-19 深圳市迪克曼科技开发有限公司 烟酰胺核糖的有机酸盐及其组合物与制备方法
CN111808156A (zh) * 2020-07-15 2020-10-23 许昌远志生物科技有限公司 一种β-烟酰胺核糖氯化物的晶型1A、晶型1B及其制备方法
EP4727544A2 (en) 2023-06-14 2026-04-22 Chromadex Inc. Nicotinamide riboside and derivatives thereof in intravenous formulations and methods of use thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1190080A (en) 1966-08-08 1970-04-29 Kyowa Hakko Kogyo Company Ltd Process for producing Nicotinamide Adenine Dinucleotide
US3728111A (en) 1971-09-21 1973-04-17 Asea Ab Method of manufacturing billets from powder
EP0981534B1 (en) 1997-02-06 2006-05-03 Inspire Pharmaceuticals, Inc. Dinucleotides and their uses
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
JP2005502580A (ja) 2000-12-15 2005-01-27 フアーマセツト・リミテツド フラビウィルス感染治療用抗ウィルス薬
US7179791B2 (en) 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
JP3748536B2 (ja) 2001-02-09 2006-02-22 三共株式会社 ピリミジンヌクレオシド誘導体の結晶
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20050020587A1 (en) 2003-07-25 2005-01-27 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US8114626B2 (en) 2004-02-10 2012-02-14 Trustees Of Dartmouth College Yeast strain and method for using the same to produce nicotinamide riboside
EP1723227A4 (en) 2004-02-10 2007-09-19 Dartmouth College NICOTINAMIDRIBOSIDE KINASE COMPOSITIONS AND METHOD FOR THEIR USE
CN1964627B (zh) 2004-06-04 2011-10-19 华盛顿大学 治疗神经病变的方法和组合物
ES2430569T3 (es) 2005-02-18 2013-11-21 Astrazeneca Ab Compuestos antibacterianos derivados de piperidina
EP2805719A1 (en) 2005-03-30 2014-11-26 Glaxosmithkline LLC Nicotinamide riboside and analogues thereof
US20070149466A1 (en) 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
WO2007061798A2 (en) 2005-11-18 2007-05-31 Cornell Research Foundation, Inc. Nicotinoyl riboside compositions and methods of use
US20070248590A1 (en) 2005-12-02 2007-10-25 Sirtris Pharmaceuticals, Inc. Modulators of CDC2-like kinases (CLKS) and methods of use thereof
WO2007136744A1 (en) 2006-05-19 2007-11-29 The Johns Hopkins University Crystal structure of a substrate complex of nampt/pbef/visfatin
JP2010513458A (ja) 2006-12-19 2010-04-30 ファイザー・プロダクツ・インク H−pgdsの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンd2の仲介による疾患を治療するためのその使用
CA2676609A1 (en) 2007-01-26 2008-07-31 Washington University Methods and compositions for treating neuropathies
EP2307378A1 (en) 2008-06-18 2011-04-13 Pfizer Limited Nicotinamide derivatives
US20100015072A1 (en) 2008-06-30 2010-01-21 Christopher Polla Topical Compositions Comprising Isonicotinamide
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー (S)−7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンの結晶形態およびその使用
WO2011005289A2 (en) 2009-06-23 2011-01-13 President And Fellows Of Harvard College Methods and kits for measuring enzyme activity
WO2011011721A2 (en) 2009-07-24 2011-01-27 Amazentis Sa Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
US8507251B2 (en) 2009-09-28 2013-08-13 Robert J. Greenstein Medium and method for culturing Mycobacterium avium subspecies paratuberculosis
WO2011081942A1 (en) 2009-12-14 2011-07-07 Cornell University Activation and activators of sirt5
EP2464249B1 (de) 2010-03-29 2013-03-13 Johannes Huber Konzentrationssteigerndes getränk
US8481711B2 (en) 2010-07-06 2013-07-09 Hidenori Kamanishi Neurite outgrowth agent
WO2012114204A2 (en) 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
US20120107888A1 (en) 2011-02-17 2012-05-03 Qteros, Inc. Modulation of fermentation products through vitamin supplementation
US20120328526A1 (en) 2011-06-27 2012-12-27 University Of Maryland, Baltimore Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof
EP3345901A3 (en) 2011-06-29 2018-09-12 President and Fellows of Harvard College Small molecules as antiaging agents
US20140256760A1 (en) 2012-07-09 2014-09-11 Noglo Llc Reduction or prevention of alcohol reaction with dietary supplements
EP2869717B8 (en) 2012-07-09 2018-07-25 NoGlo, Inc. Prevention of alcohol reaction with dietary supplements
EP2872128B1 (en) 2012-07-16 2020-02-19 Cornell University Nicotinamide riboside to treat hearing loss
WO2014059029A1 (en) 2012-10-09 2014-04-17 President And Fellows Of Harvard College Treatment of age-related and mitochondrial diseases by inhibition of hif-1 alpha function
WO2014111906A1 (en) 2013-01-21 2014-07-24 Ecole Polytechnique Federale De Lausanne (Epfl) Bioluminescence imaging of small biomolecules
SG11201507046UA (en) 2013-03-15 2015-10-29 Nusirt Sciences Inc Leucine and nicotinic acid reduces lipid levels
GB201313465D0 (en) 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
WO2015061512A1 (en) 2013-10-24 2015-04-30 The Procter & Gamble Company Skin lightening cosmetic compositions and methods
WO2015064988A1 (ko) 2013-10-29 2015-05-07 한림대학교 산학협력단 니코틴아마이드 라이보사이드를 유효성분으로 포함하는 패혈증 치료 또는 예방용 약제학적 조성물
JP6509844B2 (ja) 2013-10-30 2019-05-08 クロマデックス, インコーポレイテッドChromaDex, Inc. 皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物
BR112016010422B1 (pt) 2013-11-12 2021-08-31 Ortho-Nutra, Llc Suplemento dietético e método de tratamento para melhorar o desempenho ou energia física em um indivíduo
WO2015099842A1 (en) 2013-12-23 2015-07-02 Abbott Laboratories Hot beverage fortifier
JP2017511304A (ja) 2014-03-13 2017-04-20 ソーク インスティチュート フォー バイオロジカル スタディーズ フェキサラミン類似体ならびに作製方法および使用方法
US20150297508A1 (en) 2014-04-21 2015-10-22 William Andriette Topical Formulation to Enhance Genital Sensation and Function
US10316054B2 (en) 2014-06-02 2019-06-11 Glaxosmithkline Intellectual Property (No. 2) Limited Preparation and use of crystalline beta-D-nicotinamide riboside
WO2016011360A1 (en) 2014-07-17 2016-01-21 The Scripps Research Institute Methods and compositions for enhancing cancer therapy
CA2956163C (en) * 2014-07-24 2023-01-10 W.R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
ES2963057T3 (es) * 2015-03-09 2024-03-25 Grace W R & Co Forma cristalina de ribósido de nicotinamida
CN109562104A (zh) 2016-04-14 2019-04-02 可劳迈戴斯有限公司 烟酰胺核苷、烟酸核苷、烟酰胺单核苷酸、和烟碱基化合物衍生物在婴儿配方中的用途
WO2017218580A1 (en) * 2016-06-14 2017-12-21 Rejuvenation Therapeutics Corporation Synthetic methods for the preparation of nicotinamide riboside and related compounds
NZ803738A (en) 2016-11-11 2024-05-31 Chromadex Inc Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
EP3727400A4 (en) 2017-12-22 2021-10-20 Elysium Health, Inc. CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE
JP7675061B2 (ja) 2019-07-19 2025-05-12 バイオシント アクチェンゲゼルシャフト ニコチンアミドリボフラノシド塩の製造方法、ニコチンアミドリボフラノシド塩自体、およびその使用
CN111808156A (zh) 2020-07-15 2020-10-23 许昌远志生物科技有限公司 一种β-烟酰胺核糖氯化物的晶型1A、晶型1B及其制备方法

Also Published As

Publication number Publication date
EP3727400A1 (en) 2020-10-28
WO2019126482A1 (en) 2019-06-27
US11414407B2 (en) 2022-08-16
US12043616B2 (en) 2024-07-23
US20230063175A1 (en) 2023-03-02
CN112020363A (zh) 2020-12-01
US20210094936A1 (en) 2021-04-01
EP3727400A4 (en) 2021-10-20
JP2021506898A (ja) 2021-02-22

Similar Documents

Publication Publication Date Title
US12043616B2 (en) Crystalline forms of nicotinamide riboside chloride
US11629163B2 (en) Methods of synthesizing nicotinamide riboside
CN107428791B (zh) 烟酰胺核苷的结晶形式
JP6289659B2 (ja) 五環トリテルペン構造修飾化合物とその調製方法及び応用
CA3172203A1 (en) Process, compositions, and crystalline forms of substituted pyridinone-pyridinyl compounds
US20250145657A1 (en) Non-hormonal steroid modulators of nf-kappa beta for treatment of disease
EP3033350A1 (en) Progesterone phosphate analogs and uses related thereto
CA2973383A1 (en) Treatment of filarial diseases
FR2549834A1 (fr) Derives de triazolo-pyrimidine, leur procede de preparation et leur application therapeutique en tant que tonicardiaques
WO2024155842A1 (en) Compositions useful for modulating splicing
JP2015532263A (ja) ウリプリスタール酢酸エステルの結晶多形
US9776989B2 (en) Chromone alkaloid dysoline for the treatment of cancer and inflammatory disorders
CA2726419A1 (en) Trans-chinnamic acid derivative and preparation method and the use thereof
CN112661692A (zh) 一种异吲哚啉衍生类化合物、制备方法及减肥应用
WO2018172496A1 (en) Compounds and compositions for use in treating psoriasis
DE602004013453T2 (de) Thiomorpholinosteroidverbindungen, deren verwendung zur herstellung von die meiose steuernden medikamenten und verfahren zu deren herstellung
WO2025140361A1 (zh) 甘草次酸衍生物及其用途
CN117999072A (zh) β肾上腺素能激动剂和其使用方法
WO1990007509A1 (fr) Derives de diazabicycloalcane
JPH08104639A (ja) Il−5産生抑制剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231214

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241122

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241122

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241122

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250127

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250527

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250604

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250724

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250724

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251027

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251126

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251126